Loading...
NPI 1932507969 · West Bloomfield, MI · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Orchard Laboratories Corp is a clinical medical laboratory provider located in West Bloomfield, Michigan. This profile covers 125 Medicare and 147 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Orchard Laboratories Corp |
| Address | 7091 Orchard Lake Rd |
| City | West Bloomfield |
| State | MI |
| ZIP | 48322 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | December 8, 2014 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $53.5M |
| Medicaid | $25.3M |
ORCHARD LABORATORIES CORP reports materially larger Medicare receipts than Medicaid, with $53.5M in total Medicare revenue versus $25.3M in total Medicaid revenue, so the provider is not single‑payer but leans more heavily on Medicare by scale. This split suggests different service mixes and payer dynamics to monitor across Medicare and Medicaid contracts.
Medicare revenue is extremely concentrated: the top three Medicare codes (K1034, G0482, G0483) account for 97.7% of this provider's total Medicare revenue, and K1034 alone represents 95.8% of Medicare revenue ($52.1M). K1034 (provision of nonprescription self‑administered COVID test) ranks #1 of 30143 providers nationally (100th percentile; extreme outlier), indicating the Medicare business is dominated by high‑volume COVID test provisioning rather than a broad menu of standard clinical lab panels.
Medicaid revenue is also concentrated but split across high‑volume COVID testing and definitive drug testing: the top three Medicaid codes (U0003, G0483, G0482) account for 79.4% of Medicaid revenue, with U0003 at $10.2M (40.8%) and G0483 at $7.4M (29.9%). U0003 ranks #1 of 157 providers in‑state (100th percentile; extreme outlier) and U0005 ranks #2 of 134 (99th percentile; extreme outlier), signaling a large, high‑throughput SARS‑CoV‑2 testing operation for Medicaid alongside substantial definitive drug testing volume.
Definitive drug testing is a major service line across payers: G0483 and G0482 together comprise a large share of Medicaid revenue (G0483 $7.4M, 29.9%; G0482 $2.2M, 8.6%) and also appear on the Medicare top list (G0482 $552.2K; G0483 $450.4K). The provider ranks highly for these drug‑testing codes (Medicare G0482 ranks #22 of 1618, 99th percentile; Medicaid G0483 ranks #3 in‑state, 97th percentile), consistent with a business model that includes centralized definitive drug‑testing services in addition to COVID testing.
Operational throughput indicators support a high specimen volume operation: large claim counts include Medicaid U0003 with 147.4K claims and G0483 with 57.6K claims, while Medicare lines show high counts for K1034 (4.3M claims) and routine specimen codes such as 36415 (9.8K claims) and 80053 (5.2K claims). These volumes imply significant logistics, reporting, and billing capacity to support both mass COVID testing distribution and routine laboratory specimen handling.
Competitive standing is bifurcated: the provider is a dominant outlier for specific COVID testing codes (Medicare K1034: ranks #1 nationally, 100th percentile; Medicaid U0003: ranks #1 in‑state, 100th percentile), yet for many routine lab and multiplex codes it sits at typical or high‑percentile volumes rather than market leadership (several codes listed as "typical, unremarkable volume" at national or state percentiles). This profile indicates market leadership in targeted high‑volume COVID and selected drug testing niches rather than across general clinical laboratory services.
The provider's enrollment history (NPI enumerated 2014-12-08 (~12 years ago)) indicates it is an established entity; combined with the concentrated revenue mix, this tenure suggests an operational focus that has likely shifted to high‑volume test lines such as K1034 and U0003 over time rather than a nascent or transient billing pattern.
From a payer exposure perspective, Medicare revenue is highly dependent on a single code (K1034) and Medicaid revenue is concentrated in a small set of codes (U0003, G0483, G0482), so policy, reimbursement, or demand changes specific to COVID testing or definitive drug testing could disproportionately affect reported revenue. Monitoring utilization trends and state/national reimbursement changes for K1034, U0003, G0483, and G0482 would be prudent given the concentrated revenue sources.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
125 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 4,341,230 | $10 | $52.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 2,830 | $200 | $552.2K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,860 | $240 | $450.4K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 11,980 | $30 | $407.1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 1,010 | $150 | $155.1K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 2,000 | $60 | $122.1K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 770 | $110 | $86.5K |
| 80053 | The lab analyst performs a comprehensive metabolic panel, or CMP test in which he measures the blood level of 14 chemicals the code descriptor lists for the panel. | 5,220 | $10 | $52.2K |
| 36415 | In this procedure, the provider inserts a needle into a vein to collect a blood sample. | 9,760 | $10 | $48.8K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 500 | $70 | $37.1K |
Showing 1–10 of 125
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 125 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
125 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| G0483 | 4 | 20 | 140 | $240 | $206.2K |
| G0482 | 4 | 50 | 140 | $190 | $109.1K |
| 87798 | 2 | 20 | 380 | $30 | $107.7K |
| K1034 | 1 | 1,090 | 560 | $10 | $64.6K |
| G0480 | 4 | 30 | 270 | $110 | $63.5K |
| G0481 | 5 | 40 | 120 | $150 | $62.1K |
| 87481 | 3 | 10 | 130 | $30 | $27.2K |
| 84134 | 2 | 10 | 70 | $10 | $26.3K |
| 87637 | 6 | 20 | 80 | $140 | $23K |
| 80307 | 4 | 120 | 130 | $60 | $21.3K |
Showing 1–10 of 125
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
147 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 147,360 | $70 | $10.2M |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 57,640 | $130 | $7.4M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 24,190 | $90 | $2.2M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 97,930 | $20 | $1.9M |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 6,460 | $100 | $664.9K |
| 87798 | The lab analyst performs a test for an infectious agent not specified in another code using an amplified nucleic acid probe technique. Use this code if you know the laboratory technique is amplified… | 13,420 | $50 | $644K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 9,650 | $60 | $540.6K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 16,190 | $20 | $307.5K |
| 87633 | The lab analyst performs a test to identify a respiratory virus using amplified nucleic acid probe technique. He may also use a multiplex reverse transcription technique. The provider does this for… | 1,550 | $160 | $242K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 7,750 | $10 | $108.4K |
Showing 1–10 of 147
How this provider's Medicaid billing volume and revenue compare to other Michigan providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Michigan median
147 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 3 | 60 | 1,310 | $130 | $1.1M |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 70 | 680 | $100 | $604K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 1 | 160 | 2,720 | $60 | $546.6K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 4 | 50 | 650 | $80 | $298.5K |
| 87637 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, influenza B, and respiratory syncytial virus (RSV)… | 62 | 130 | 1,180 | $80 | $231.2K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but… | 48 | 150 | 2,250 | $30 | $202.4K |
| 87591 | The lab analyst performs a lab test for Neisseria gonorrhoeae, also called GC, using amplified nucleic acid probe technique. | 61 | 180 | 2,600 | $20 | $162K |
| 87636 | The lab analyst performs the technical steps to detect and differentiate severe acute respiratory syndrome coronavirus 2 (SARS–CoV–2), influenza A, and influenza B using a multiplex amplified nucleic… | 11 | 140 | 290 | $80 | $161.3K |
| 87491 | The lab analyst performs a test for Chlamydia trachomatis using amplified nucleic acid probe technique. | 60 | 190 | 2,610 | $20 | $160.2K |
| 80307 | The lab analyst performs presumptive drug test(s) via instrumented chemistry analyzers to screen for any number of drug classes on a single date. | 60 | 240 | 2,430 | $20 | $152.2K |
Showing 1–10 of 147
Other providers in the same ZIP code as Orchard Laboratories Corp, ranked by combined Medicare and Medicaid revenue.
| Provider | State | Taxonomy | Medicare Revenue | Medicaid Revenue |
|---|---|---|---|---|
| Wellstreet Urgent Care Of Michigan | MI | Urgent Care Clinic/Center | $0 | $37.5M |
| Henry Ford Health System | MI | General Acute Care Hospital | $0 | $19.3M |
| M&y Care, LLC | MI | Home Health Agency | $0 | $15.8M |
| Charter Township Of West Bloomfield | MI | Ambulance | $751.8K | $602.7K |
| Aaron Cetner | MI | MOHS-Micrographic Surgery Physician | $892.5K | $0 |
| Jason Hafron | MI | Urology Physician | $487.3K | $0 |
| Leonard Cetner | MI | Dermatology Physician | $409.5K | $0 |
| Hugh Pabarue | MI | Internal Medicine Physician | $396.7K | $0 |
| James Relle | MI | Urology Physician | $394.4K | $0 |
| Hua Gao | MI | Ophthalmology Physician | $380.5K | $0 |
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.